Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 16/20 | 0.35 |
| ▸ | MAOB | P27338 | 8/20 | 0.35 |
| ▸ | MAOA | P21397 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516473 | 0.88 | EGFR (0.42) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5510707 | 0.87 | KDM1A (0.37) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5512653 | 0.87 | EGFR (0.34) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5505480 | 0.87 | MET (0.38) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5512758 | 0.86 | EGFR (0.33) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL14437204 | 0.85 | CDK1 (0.40) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5514567 | 0.85 | EGFR (0.41) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5519374 | 0.85 | KDM1A (0.39) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5509144 | 0.84 | EGFR (0.40) | EGFRSRCABL1FLT1KDR | |
| SCHEMBL5511506 | 0.83 | KDM1A (0.36) | EGFRSRCABL1FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | claimed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | claimed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | EGFR 2116/4885SRC 940/4885ABL1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.